Company Filing History:
Years Active: 2013-2014
Title: Harmut Strobel: Innovator in Pharmaceutical Chemistry
Introduction
Harmut Strobel is a notable inventor based in Frankfurt am Main, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that modulate the expression of endothelial nitric oxide synthase.
Latest Patents
Strobel holds 2 patents related to heteroaryl-substituted amides. His latest patents include:
1. Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, which are valuable pharmacologically active compounds. These compounds are designed to upregulate the expression of endothelial nitric oxide synthase, making them applicable in treating various cardiovascular disorders such as atherosclerosis and hypertension.
2. Heteroaryl-substituted amides comprising a saturated linker group, which also serve similar pharmacological purposes. These inventions focus on the preparation of compounds that can stimulate the expression of endothelial nitric oxide synthase and are intended for use in the manufacture of medicaments for treating cardiovascular diseases.
Career Highlights
Harmut Strobel is currently associated with Sanofi, a leading global healthcare company. His work at Sanofi emphasizes the importance of innovative pharmaceutical solutions that address critical health issues.
Collaborations
Strobel has collaborated with notable colleagues in his field, including Paulus Wohlfart and Gerhard Zoller. These collaborations have likely contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
Harmut Strobel's contributions to pharmaceutical chemistry through his innovative patents highlight his role as a significant inventor in the field. His work continues to impact the treatment of cardiovascular disorders, showcasing the importance of research and innovation in healthcare.